ClinicalTrials.gg
CompletedNCT04558957POLFLEBUpdated Jun 18, 2023

Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With Flebogrif in Patients With Great Saphenous Vein Insufficiency

An interventional study of FLEBOGRIF in Chronic Venous Insufficiency, CVI, sponsored by Balton Sp.zo.o.. Completed at 4 sites in Poland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2019, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The objective of the study is to collect clinical data of patients in whom Flebogrif® will have been used for mechanochemical ablation of incompetent veins in the follow-up period, as related to the safety, clinical effectiveness, properties and advantages of Flebogrif®.

The proposed study is a prospective, multi-centre clinical trial assessing the safety, efficacy and quality of Flebogrif® in a population of patients with the incompetent great saphenous vein, who require surgical treatment.

02

Conditions studied

  • Chronic Venous Insufficiency, CVI
03

In context

Lead sponsor

Balton Sp.zo.o. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Study inclusion criteria:

  1. Signing the Form by the patient found eligible for the treatment with the mechanochemical method
  2. The patient declares willingness to participate in the study and in the monitoring visits envisaged in the study protocol
  3. A patient with diagnosed varicose veins and diagnosed great saphenous vein (GSV) insufficiency confirmed by ultrasound (CEAP class C2-C6)
  4. Favourable anatomy enabling the introduction of the Flebogrif® guidewire/catheter and positioning of its top part at the dedicated site (2-3 cm below SFJ)
  5. Diameter of the treated vein of 4-10 mm
  6. No data or no history indicating an allergy to the sclerosing chemicals used in the mechanochemical method (polidocanol), on the basis of the information obtained from the patient and the available medical records
  7. No clinical symptoms indicating (chronic, critical) lower limb ischaemia precluding the use of compression, on the basis of a physical examination or, in unclear cases, of a Doppler ultrasound examination
  8. No medical information or no history of coagulation system dysfunction of the type of thrombophilia or bleeding diatheses
  9. No cutaneous lesions (purulent, bullous) within the limb found eligible for treatment with the mechanochemical method
  10. No clinical data indicating recent thrombosis within the deep vein system
  11. No clinical data on diabetes with vascular complications
  12. No clinical data indicating an active neoplastic process

Study exclusion criteria:

  1. Recent deep vein thrombosis or occlusion
  2. Congenital disorders with associated occlusion of deep system veins
  3. Pregnancy and breast-feeding
  4. Lower limb ischaemia
  5. Severe lymphatic oedema
  6. Bleeding diatheses
  7. Documented allergic reaction to sclerosing chemicals used in mechanochemical vein ablation
  8. Purulent dermatoses affecting the limb found eligible for treatment with mechanochemical vein ablation
  9. Previous procedures on insufficiency veins of the superficial system
  10. Acute infection
  11. History of great saphenous vein thrombosis
  12. End-stage kidney disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    FLEBOGRIF

    Interventions will be performed using Flebogrif catheter.

    Device: FLEBOGRIF

Interventions

  • DeviceFLEBOGRIF

    The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint: Occlusion rate

    Primary efficacy endpoint: Occlusion rate of the great saphenous vein in the treated segment at 3 months

    Time frame: 3 months

  2. Primary safety endpoint: Rate of SAE

    Primary safety endpoint: Rate of serious adverse events within 30 days after the procedure

    Time frame: 30 days after the procedure

Secondary outcomes

  1. Occlusion rate

    Occlusion rate of the great saphenous vein at 1, 6, 12, 18 and 24 months

    Time frame: 1, 6, 12, 18, 24 months

  2. Number of Participants with no reflux in treated segment of the vein

    Number of Participants with no reflux in the treated segment of the great saphenous vein at 1, 3, 6, 12, 18 and 24 months

    Time frame: 1, 3, 6, 12, 18, 24 months

  3. Change in quality of life by Aberdeen Varicose Vein Questionnaire

    Change in quality of life measured with the use of the Aberdeen Varicose Vein Questionnaire at 12 and 24 months Scale score: 0-100; higher score = worse outcome.

    Time frame: 12 and 24 months

  4. Clinical success - changes in rVCSS

    Clinical success, defined as change in rVCSS classification (Revised Venous Clinical Severity Score) after 12 and 24 months Scale score 0-30; higher score = worse outcome.

    Time frame: 12 and 24 months

  5. Assessment of pain during the procedure

    Assessment of pain during the procedure (Visual Analogue Pain Scale, VAPS) ranging from 0 to 10. Pain assessed using the Visual Analogue Scale (range 0-10; 0 = no pain; 2 = mild pain, 4 = nagging, annoying pain; 6 = severe pain; 8 = very severe pain; 10 = unbearable pain).

    Time frame: During procedure

  6. Assessment of pain within 0-7 days after the procedure: Visual Analogue Scale

    Assessment of pain within 0-7 days after the procedure (VAPS 0-10, daily assessment). Pain assessed using the Visual Analogue Scale (range 0-10; 0 = no pain; 2 = mild pain, 4 = nagging, annoying pain; 6 = severe pain; 8 = very severe pain; 10 = unbearable pain).

    Time frame: 0-7 days after procedure

  7. Assessment of the need for analgesic treatment

    Assessment of the need for analgesic treatment after the procedure (0-7 days)

    Time frame: 0-7 days after procedure

  8. Period needed to resume normal activities

    Period needed to resume normal activities

    Time frame: up to 2 years after the treatment

  9. Period needed to return to work (sick leave period)

    Period needed to return to work (sick leave period)

    Time frame: up to 2 years after the treatment

  10. Complications rate

    Complications rate including deep vein thrombosis, nerve damage, infections, etc.

    Time frame: up to 2 years after the treatment

07

Study locations

4 sites
  • Centrum Chirurgii i Stomatologii Jaworuccy Sp. P.
    Gorzów Wielkopolski, 66-400, Poland
  • Centrum Medyczne Angelius Provita; Europejskie Centrum Flebologii
    Katowice, 40-611, Poland
  • Medyczne Centrum Nałęczów sp. z o.o.
    Lublin, 20-950, Poland
  • Klinika Dorobisz
    Wrocław, 54-130, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Aug 2021, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 22, 2020
StartActual
Aug 8, 2019
Primary completionActual
Aug 12, 2021
CompletionActual
Apr 28, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04558957
Lead sponsor
Balton Sp.zo.o.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Sep 22, 2020
Start date
Aug 8, 2019
Primary completion
Aug 12, 2021
Completion
Apr 28, 2023
Last update
Jun 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion